Role of natural killer cells in antitumor resistance

Annual Review of Biomedical Sciences

Volumn 7, Issue , 2005, Pages 127-148

  Kaneno, Ramon ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Cell activation; Cytotoxicity; Natural killer; Tumor immunology

Indexed keywords

BATROXOBIN; GANGLIOTETRAOSYLCERAMIDE; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PK 136; PERFORIN; RECOMBINANT ALPHA INTERFERON; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; ANGIOGENESIS; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; BLOOD CLOTTING DISORDER; BONE MARROW TRANSPLANTATION; BURKITT LYMPHOMA; CANCER CELL CULTURE; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CANCER INHIBITION; CANCER PATIENT; CANCER RESISTANCE; CANCER SUSCEPTIBILITY; COLON CARCINOGENESIS; COLON CARCINOMA; COLORECTAL CARCINOMA; DENDRITIC CELL; DIARRHEA; EFFECTOR CELL; HOST RESISTANCE; HUMAN; IMMUNOSURVEILLANCE; LIVER METASTASIS; LUNG DISEASE; LUNG METASTASIS; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA CELL; METASTASIS INHIBITION; NATURAL KILLER T CELL; NONHUMAN; REVIEW; SKIN TOXICITY; T LYMPHOCYTE SUBPOPULATION; THROMBOCYTOPENIA;

ANIMALIA;

EID: 32044458595     PISSN: 18068774     EISSN: 18068774     Source Type: Journal    
DOI: None     Document Type: Review

References (139)

1. Adachi W, Usuda N, Sugenoya A, Iida F. Immune-competent cells of regional lymph nodes in colorectal cancer patients: II. Immunohistochemical analysis of Leu-7+ cells. J Surg Oncol 1990;45:234-41.
2. Alimonti JB, Shi L, Baijal PK, Greenberg AH. Granzyme B induces BID-mediated cytochrome c release and mitochondrial permeability transition. J Biol Chem 2001;276:6974-82.
3. An T, Sood U, Pietruk T, Cummings G, Hashimoto K, Crissman JD. In situ quantitation of inflammatory mononuclear cells in ductal infiltrating breast carcinoma. Relation to prognostic parameters. Am J Pathol 1987;128:52-60.
4. Aparicio-Pages NM, Verspaget HW, Pena SA, Lamers CB. Impaired local natural killer cell activity in human colorectal carcinomas. Cancer Immunol Immunother 1989;28:301-4.
5. Arienti F, Belli F, Rivoltini L, Gambacorti-Passerini C, Furlan L, Mascheroni L, Prada A, Rizzi M, Marchesi E, Vaglini M. Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2. Cancer Immunol Immunother 1993;36:315-22.
6. Arisawa Y, Kubota T, Suto A, Kodaira S, Ishibiki K, Abe O. Nude mouse resists hepatic metastasis of the allogeneic tumor, colon-26. Jpn J Surg 1990; 20: 487-90.
7. Balch CM, Riley LB, Bae YJ, Salmeron MA, Platsoucas CD, von Eschenbach A, Itoh K. Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Arch Surg 1990;125:200-5.
8. Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 1989;70:175-82.
9. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285:727-9.
10. Berke G. The Fas-based mechanism of lymphocytotoxicity. Hum Immunol 1997;54:1-7.
11. Bossi G, Griffiths GM. Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells. Nature Med 1999;5:90-6.
12. Browne KA, Johnstone RW, Jans DA, Trapani JA. Filamin (280-kDa actin-binding protein) is a caspase substrate and is also cleaved directly by the cytotoxic T lymphocyte protease granzyme B during apoptosis. J Biol Chem 2000;275:39262-6.
13. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately MK. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993;178:1223-30.
14. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970;13:1-7.
15. Burshtyn DN, Scharenberg AM, Wagtmann N, Rajagopalan S, Berrada K, Yi T, Kinet JP, Long EO. Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor. Immunity 1996;4:77.
16. Campbell KS, Dessing M, Lopez-Botet M, Cella M, Colonna M. Tyrosine phosphorylation of a human killer inhibitory receptor recruits protein tyrosine phosphatase 1C. J Exp Med 1996;184:93.
17. Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, Anderson D, Eisenmann J, Grabstein K, Caligiuri MA. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 1994;180:1395-403.
18. Carson WE, Ross ME, Baiocchi RA, Marien MJ, Boiani N, Grabstein K, Kaligiuri MA. Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-gamma by natural killer cells in vitro. J Clin Invest 1995;96:2578-82.
19. Cella M, Dohring C, Samaridis J, Dessing M, Brockhaus M, Lanzavecchia A, Collona M. A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing. J Exp Med 1997;185:1743-51.
20. Chang C, Rodriguez A, Carretero M, Lopez-Botet M, Phillips JH, Lanier LL. Molecular characterization of human CD94: a type II membrane glycoprotein related to the C-type lectin superfamily. Eur J Immunol 1995;25:2433-37.
21. Chiodoni C, Stoppacciaro A, Sangaletti S, Gri G, Cappetti B, Koezuka Y, Colombo MP. Different requirements for alpha-galactosylceramide and recombinant IL-12 antitumor activity in the treatment of C-26 colon carcinoma hepatic metastases. Eur J Immunol 2001;31:3101-10.
22. Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, Martos JA, Moreno M. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 1997;79:2320-8.
23. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001a;22:633-40.
24. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA. Human natural killer cells: a unique innate immunoregulatory role for the CD56 (bright) subset. Blood 2001b;97:3146-51.
25. D'Andrea A, Rengaraju M, Valiante NM, Chehimi J, Kubin M, Aste M, Chan SH, Kobayashi M, Young D, Nickbarg E. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med 1992;176:1387-98.
26. Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 2000;1:119-26.
27. Duda DG, Sunamura M, Lozonschi L, Kodama T, Egawa S, Matsumoto G, Shimamura H, Shibuya K, Takeda K, Matsuno S. Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. Cancer Res 2000;60:1111-6.
28. Dunne J, Lynch S, O'Farrelly C, Todryk S, Hegarty JE, Feighery C, Doherty DG. Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15. J Immunol 2001;167:3129-38.
29. Fanger NA, Borges L, Cosman D. The leukocyte immunoglobulin-like receptors (LIRs): a new family of immune regulators. J Leukoc Biol 1999;66:231-6.
30. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood 2001;97:14-32.
31. Fletcher JM, Prentice HG, Grundy JE. Natural killer cell lysis of cytomegalovirus (CMV)-infected cells correlates with virally induced changes in cell surface lymphocyte function-associated antigen-3 (LFA-3) expression and not with the CMV-induced down-regulation of cell surface class I HLA. J Immunol 1998;161:2365-74.
32. Gaspari AA. Dermatologic changes associated with adoptive immunotherapy of cancer. Semin Dermatol 1991;10:178-87.
33. Giebel S, Locatelli E, Lamparelli T, Velardi A, Davies S, Frumento G, Maccario R, Bonetti F, Wojnar J, Martinetti M, Frassoni F, Giorgiani G, Bacigalupo A, Holowiecki J. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003;102:814-9.
34. Golub SH, D'Amore P, Rainey M Systemic administration of human leukocyte interferon to melanoma patients. II. Cellular events associated with changes in natural killer cytotoxicity. J Natl Cancer Inst 1982a;68:711-7.
35. Golub SH, Dorey F, Hara D, Morton DL, Burk MW. Systemic administration of human leukocyte interferon to melanoma patients. I. Effects on natural killer function and cell population. J Natl Cancer Inst 1982b;68:703-10.
36. Grabstein KH, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, Fung V, Beers C, Richardson J, Schoenborn MA, Ahdieh M. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 1994;264:965-8.
37. Griffin JD, Hercend T, Beveridge R, Schlossman SF. Characterization of an antigen expressed by human natural killer cells. J Immunol 1983;130:2947-51.
38. Griffiths GM, Isaaz S. Granzymes A and B are targeted to the lytic granules of lymphocytes by the mannose-6-phosphate receptor. J Cell Biol 1993;120:885-96.
39. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982;155:1823-41.
40. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 1999;96:6879-84.
41. Guarini A, Sanavio F, Novarino A, Gillio Tos A, Aglietta M, Foa R. Thrombocytopenia in acute leukaemia patients treated with IL2: cytolytic effect of LAK cells on megakaryocytic progenitors. Br J Haematol 1991;79:451-6.
42. Harning R, Koo GC, Szalay J. Regulation of the metastasis of murine ocular melanoma by natural killer cells. Invest Ophthalmol Vis Sci 1989;30:1909-15.
43. Hayakawa M, Hatano T, Ogawa Y, Gakiya M, Ogura H, Osawa A. Treatment of advanced renal cell carcinoma using regional arterial administration of lymphokine-activated killer cells in combination with low doses of rIL-2. Urol Int 1994;53:117-24.
44. Hayakawa Y, Kelly JM, Westwood JA, Darcy PK, Diefenbach A, Raulet D, Smyth MJ. Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin. J Immunol 2002;169:5377-81.
45. Heibein JA, Goping IS, Barry M, Pinkoski MJ, Shore GC, Green DR, Bleackley RC. Granzyme B-mediated cytochrome c release is regulated by the Bcl-2 family members bid and Bax. J Exp Med 2000;192:1391-402.
46. Henney CS, Kuribayashi K,. Kern DE, Gillis S. Interleukin-2 augments natural killer cell activity. Nature 1981;291:335-8.
47. Herberman RB, Bartram S, Haskill JS, Nunn M, Holden HT, West WH. Fc receptors on mouse effector cells mediating natural cytotoxicity against tumor cells. J Immunol 1977;119:322-6.
48. Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer 1975;16:216-29.
49. Hersey P, Hobbs A, Edwards A, McCarthy WH, McGovern VJ. Relationship between natural killer cell activity and histological features of lymphocyte infiltration and partial regression of the primary tumor in melanoma patients. Cancer Res 1982;42:363-8.
50. Horny HP, Horst HA. Lymphoreticular infiltrates in adenocarcinoma of the large intestine. Pathol Res Pract 1987;182:222-7.
51. Ibayashi Y, Yamaki T, Kawahara T, Daibo M, Kubota T, Uede T, Tanabe S, Hashi K. Effect of local administration of lymphokine-activated killer cells and interleukin-2 on malignant brain tumor patients. Neurol Med Chir 1993;33:448-57.
52. Irmler M, Hertig S, MacDonald HR, Sadoul R, Becherer JD, Proudfoot A, Solari R, Tschopp J. Granzyme A is an interleukin 1 beta-converting enzyme. J Exp Med 1995;181:1917-22.
53. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, Aridome K, Hokita S, Aikou T. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 2000;88:577-83.
54. Kasai M, Iwamori M, Nagai Y, Okumura K, Tada T. A glycolipid on the surface of mouse natural killer cells. Eur J Immunol 1980;10:175-80.
55. Kay HD, Bonnard GD, West WH, Herberman RB. A functional comparison of human Fc-receptor-bearing lymphocytes active in natural cytotoxicity and antibody-dependent cellular cytotoxicity. J Immunol 1977;118:2058-66.
56. Kayagaki, N., N. Yamaguchi, M. Nakayama, K. Takeda, H. Akiba, H. Tsutsui, Okamura H, Nakanishi K, Okumura K, Yagita H. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. J Immunol 1999;163:1906-13.
57. Keilholz U, Schlag P, Tilgen W, Brado B, Galm F, Gorich J, Kauffmann GW, Moller P, Schneider S, Hunstein W. Regional administration of lymphokine-activated killer cells can be superior to intravenous application. Cancer 1992;69:2172-5.
58. Kiessling R, Klein E, Pross H, Wigzell H. "Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol 1975;5:117-21.
59. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Loudon R, Sherman F, Perussia B, Trinchieri G. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. Exp Med 1989;170:827-45.
60. Kodama T, Takeda K, Shimozato O, Hayakawa Y, Atsuta M, Kobayashi K, Ito M, Yagita H, Okumura K. Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12. Eur J Immunol 1999;29:1390-6.
61. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 1986a;136:4480-6.
62. Lanier LL, Cwirla S, Federspiel N, Phillips JH. Human natural killer cells isolated from peripheral blood do not rearrange T cell antigen receptor beta chain genes. J Exp Med 1986b;163:209-14.
63. Lanier LL, Ruitenberg JJ, Phillips JH. Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes. J Immunol 1988;141:3478-85.
64. Lanier LL, Testi R, Bindl J, Phillips JH. Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med 1989;169:2233-8.
65. Lieberman J, Fany Z. Nuclear war: the granzyme A-bomb. Curr Op Immunol 2003;15:553-9.
66. Lieberman J. Cell death and immunity: The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal Nature Rev Immunol 2003;3:361-70.
67. Lieberman MD, Sigal RK, Williams NN 2nd, Daly JM. Natural killer cell stimulatory factor (NKSF) augments natural killer cell and antibody-dependent tumoricidal response against colon carcinoma cell lines. J Surg Res 1991;50:410-5.
68. Ljunggren HG, Kärre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 1990;11:237.
69. Lo CH, Lee SC, Wu PY, Pan WY, Su J, Cheng CW, Roffler SR, Chiang BL, Lee CN, Wu CW, Tao MH. Antitumor and antimetastatic activity of IL-23. J Immunol 2003;171:600-7.
70. Lotzova E, Ades EW. Natural killer cells: definition, heterogeneity, lytic mechanism, functions and clinical application. Highlights of the Fifth International Workshop on natural killer cells, Hilton Head Island, N.C., March 1988.
71. Lowin-Kropf B, Held W. Positive impact of inhibitory Ly49 receptor-MHC class I interaction on NK cell development. J Immunol 2000;165:91-5.
72. Lowin-Kropf B, Kunz B, Beermann E, Held W. Impaired natural killing of MHC class I-deficient targets by NK cells expressing a catalytically inactive form of SHP-1. J Immunol 2000;165:1314-21.
73. Makrigiannis AP, Pau AT, Saleh A, Winkler-Pickett R, Ortaldo JR, Anderson SK. Class I MHC-binding characteristics of the 129/j ly49 repertoire. J Immunol 2001;166:5034-43.
74. Malnati MS, Peruzzi M, Parker KC, Biddison WE, Ciccone E, Moretta A, Long EO. Peptide specificity in the recognition of MHC class I by natural killer cell clones. Science 1995;267:1016-8.
75. Martinotti A, Stoppacciaro A, Vagliani M, Melani C, Spreafico E, Wysocka M, Parmiani G, Trinchieri G, Colombo MP. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur J Immunol 1995;25:137-46.
76. Masucci MG, Masucci G, Klein E, Berthold W. Target selectivity of interferon-induced human killer lymphocytes related to their Fc receptor expression. Proc Natl Acad Sci USA 1980;77:3620-4.
77. Menier C, Riteau B, Carosella ED, Rouas-Freiss N. MICA triggering signal for NK cell tumor lysis is counteracted by HLA-G1-mediated inhibitory signal. Int J Cancer 2002;100:63-70.
78. Middleton D, Curran M, Maxwell L. Natural killer cells and their receptors Transplant Immunol 2002;10:147-64.
79. Mrozek E, Anderson P, Caligiuri MA. Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood 1996;87:2632-40.
80. Natarajan K, Dimasi N, Wang J, Mariuzza RA, Margulies DH. Structure and function of natural killer cell receptors: multiple molecular solutions to self, nonself discrimination. Annu Rev Immunol 2002;20:853-85.
81. Nishikawa K, Saito S, Morii T, Kato Y, Narita N, Ichijo M, Ohashi Y, Takeshita T, Sugamura K. Differential expression of the interleukin 2 receptor beta (p75) chain on human peripheral blood natural killer subsets. Int Immunol 1990;2:481-6.
82. Nitta T, Yagita H, Sato K, Okumura K. Involvement of CD56 (NKH-1/Leu-19 antigen) as an adhesion molecule in natural killer-target cell interaction. J Exp Med 1989;170:1757-61.
83. Ohteki T, Ho S, Suzuki H, Mak TW, Ohashi PS. Role for IL-15/IL-15 receptor beta-chain in natural killer 1.1+ T cell receptor-alpha beta+ cell development. J Immunol 1997;159:5931-5.
84. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, Vega F, Yu N, Wang J, Singh K, Zonin F, Vaisberg E, Churakova T, Liu M, Gorman D, Wagner J, Zurawski S, Liu Y, Abrams JS, Moore KW, Rennick D, de Waal-Malefyt R, Hannum C, Bazan JF, Kastelein RA. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000;13:715-25.
85. Orange JS, Fassett MS, Koopman LA, Boyson JE, Strominger JL. Viral evasion of natural killer cells. Nat Immunol 2002;3:1006-12.
86. Ortaldo JR, Oldham RK, Cannon GC, Herberman RB. Specificity of natural cytotoxic reactivity of normal human lymphocytes against a myeloid leukemia cell line. J Natl Cancer Inst 1977;59:77-82.
87. Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, Pflanz S, Zhang R, Singh KP, Vega F, To W, Wagner J, O'Farrell AM, McClanahan T, Zurawski S, Hannum C, Gorman D, Rennick DM, Kastelein RA, de Waal Malefyt R, Moore KW. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002;168:5699-708.
88. Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, Johnston J, Madden K, Xu W, West J, Schrader S, Burkhead S, Heipel M, Brandt C, Kuijper JL, Kramer J, Conklin D, Presnell SR, Berry J, Shiota F, Bort S, Hambly K, Mudri S, Clegg C, Moore M, Grant FJ, Lofton-Day C, Gilbert T, Rayond F, Ching A, Yao L, Smith D, Webster P, Whitmore T, Maurer M, Kaushansky K, Holly RD, Foster D. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000;408:57-63.
89. Parrish-Novak J, Foster DC, Holly RD, Clegg CH. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc Biol 2002; 72: 856-63.
90. Phillips JH, Lanier LL. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 1986;164:814-25.
91. Ramani P, Balkwill FR. Action of recombinant alpha interferon against experimental and spontaneous metastases in a murine model. Int J Cancer 1989;43:140-6.
92. Reynolds CW, Timonen T, Herberman RB. Natural killer (NK) cell activity in the rat. I. Isolation and characterization of the effector cells. J Immunol 1981; 127: 282-7.
93. Richard V, Bernier M, Themelin L, Bron D, Sculier JP. Blood coagulation abnormalities during adoptive immunotherapy with interleukin-2 (r-Met Hu IL-2 [ala 125]). Ann Oncol 1991;2:67-8.
94. Ritz J, Campen TJ, Schmidt RE, Royer HD, Hercend T, Hussey RE, Reinherz EL. Analysis of T-cell receptor gene rearrangement and expression in human natural killer clones. Science 1985;228:1540-3.
95. Robertson MJ, Cameron C, Atkins MB, Gordon MS, Lotze MT, Sherman ML, Ritz J. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin Cancer Res 1999;5:9-16.
96. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990;76:2421-38.
97. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989;210:474-85.
98. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, Urbani E, Negrin RS, Martelli MF, Velardi A. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999;94:333-9.
99. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni E, Aversa E, Martelli ME, Velardi A. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097-100.
100. Sacchi M, Vitolo D, Sedlmayr P, Rabinowich H, Johnson JT, Herberman RB, Whiteside TL. Induction of tumor regression in experimental model of human head and neck cancer by human A-LAK cells and IL-2. Int J Cancer 1991;47:784-91.
101. Saksela E, Timonen T, Ranki A, Hayry P. Morphological and functional characterization of isolated effector cells responsible for human natural killer activity to fetal fibroblasts and to cultured cell line targets. Immunol Rev 1979;44:71-123.
102. Sanada E, Fuchimoto S, Orita K. Synergistic antiproliferative effect of the combination of natural human tumor necrosis factor-alpha and natural murine interferon-alpha/ beta against colon-26 adenocarcinoma hepatic metastases in a murine model. Acta Med Okayama 1990;44:217-22.
103. Santoni A, Herberman RB, Holden HT. Correlation between natural and antibody-dependent cell-mediated cytotoxicity against tumor targets in the mouse. I. Distribution of the reactivity. J Natl Cancer Inst 1979;62:109-16.
104. Sauer H, Pratsch L, Tschopp J, Bhakdi S, Peters R. Functional size of complement and perform pores compared by confocal laser scanning microscopy and fluorescence microphotolysis. Biochim Biophys Acta 1991;1063:137-46.
105. Screpanti V, Wallin RPA, Ljunggren H-G, Grandien A. A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells. J Immunol 2001;167:2068-73.
106. Sharif-Askari E, Alam A, Rheaume E, Beresford PJ, Scotto C, Sharma K, Lee D, DeWolf WE, Nuttall ME, Lieberman J, Sekaly RP. Direct cleavage of the human DNA fragmentation factor-45 by granzyme B induces caspase-activated DNase release and DNA fragmentation. EMBO J 2001;20:3101-13.
107. Shibuya M, Niitani H, Aoyama A, Kawachi S, Nukariya N, Baba M, Iizuka K, Sakai S, Ohtsuka M. Antimetastatic effect of defibrinogenation with batroxobin depends on the natural killer activity of host in mice. J Cancer Res Clin Oncol 1990;116:168-72.
108. Shimizu Y, DeMars R. Demonstration by class I gene transfer that reduced susceptibility of human cells to natural killer cell-mediated lysis is inversely correlated with HLA class I antigen expression. Eur J Immunol 1989;19:447-51.
109. Shinkai Y, Takio K, Okumura K. Homology of perform to the ninth component of complement (C9). Nature 1988;334: 25-7.
110. Simony J, Rossi JF, Shishehian B, Ursule E, Radal M, Pujol H. Characterization of proliferative cells in malignant melanomas and their inflammatory infiltrates. Cancer Detect Prev 1991;15:183-7.
111. Soderstrom K, Corliss B, Lanier LL Phillips JH. CD94/NKG2 is the predominant inhibitory receptor involved in recognition of HLA-G by decidual and peripheral blood NK cells. J Immunol 1997;159:1072-5.
112. Sparano JA, Dutcher JP, Kaleya R, Caliendo G, Fiorito J, Mitsudo S, Shechner R, Boley SJ, Gucalp R, Ciobanu N. Colonic ischemia complicating immunotherapy with interleukin-2 and interferon-alpha. Cancer 1991;68:1538-44.
113. Storkus WJ, Alexander J, Payne JA, Dawson JR, Cresswell P. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc Natl Acad Sci USA 1989;86:2361-4.
114. Suidan HS, Clemetson KJ, Brown-Luedi M, Niclou SP, Clemetson JM, Tschopp J, Monard D. The serine protease granzyme A does not induce platelet aggregation but inhibits responses triggered by thrombin. Biochem J 1996;315:939-45.
115. Suttles J, Schwarting GA, Hougland MW, Stout RD. Expression of asialo GM1 on a subset of adult murine thymocytes: histological localization and demonstration that the asialo GM1-positive subset contains both the functionally mature and the proliferating thymocyte subpopulations. J Immunol 1987;138:364-72.
116. Suzuki H, Duncan GS, Takimoto H, Mak TW. Abnormal development of intestinal intraepithelial lymphocytes and peripheral natural killer cells in mice lacking the IL-2 receptor beta chain. J Exp Med 1997;185:499-505.
117. Suzuki N, Suzuki T, Engleman EG. Evidence for the involvement of CD56 molecules in alloantigen-specific recognition by human natural killer cells. J Exp Med 1991;173:1451-61.
118. Thomas DA, Du C, Xu M, Wang X, Ley TJ. DFF45/ICAD can be directly processed by granzyme B during the induction of apoptosis. Immunity 2000;12:621-32.
119. Timonen T, Saksela E, Ranki A, Hayry P. Fractionation, morphological and functional characterization of effector cells responsible for human natural killer activity against cell-line targets. Cell Immunol 1979a;48:133-48.
120. Timonen T, Ranki A, Saksela E, Hayry P. Human natural cell-mediated cytotoxicity against fetal fibroblasts. III. Morphological and functional characterization of the effector cells. Cell Immunol 1979b;48:121-32.
121. Timonen T, Saksela E. Isolation of human NK cells by density gradient centrifugation. J Immunol Methods 1980;36:285-91.
122. Tomasello E, Olcese L, Vely F, Geourgeon C, Blery M, Moqrich A, Gautheret D, Djabali M, Mattei MG, Vivier E. Gene structure, expression pattern, and biological activity of mouse killer cell activating receptor-associated protein (KARAP)/DAP-12. J Biol Chem 1998;273:34,115-9.
123. Trambas CM, Griffiths GM. Delivering the kiss of death. Nat Immunol 2003; 4: 399-403.
124. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989;47:187-376.
125. Ueda Y, Yamagishi H, Tanioka Y, Fujiwara H, Fuji N, Itoh T, Fujiki H, Yoshimura T, Oka T. Clinical application of adoptive immunotherapy and IL-2 for the treatment of advanced digestive tract cancer. Hepatogastroenterology 1999;46:1274-9.
126. van den Broek MF, Kagi D, Zinkernagel RM, Hengartner H. Perforin dependence of natural killer cell-mediated tumor control in vivo. Eur J Immunol 1995;25:3514-6.
127. Villani E, Galimberti M, Rizzi M, Manzi R. Pulmonary toxicity of recombinant interleukin-2 plus lymphokine-activated killer cell therapy. Eur Respir J 1993;6:828-33.
128. Villegas FR, Coca S, Villarrubia VG, Jimenez R, Chillon MJ, Jareno J, Zuil M, Callol L. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 2002;35:23-8.
129. Vujanovic NL, Basse P, Herberman RB, Whiteside TL. Antitumor functions of natural killer cells and control of metastases. Methods 1996; 9: 394-408.
130. West WH, Cannon GB, Kay HD, Bonnard GD, Herberman RB. Natural cytotoxic reactivity of human lymphocytes against a myeloid cell line: characterization of effector cells. J Immunol 1977;118:355-61.
131. Willerford DM, Chen J, Ferry JA, Davidson L, Ma A, Alt FW. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity 1995;3:521-30.
132. Wolf BB, Schuler M, Echeverri F, Green DR Caspase-3 is the primary activator of apoptotic DNA fragmentation via DNA fragmentation factor-45/inhibitor of caspase-activated DNase inactivation. J Biol Chem 1999;274:30651-6.
133. Wu J, Cherwinski H, Spies T, Phillips JH, Lanier LL. DAP10 and DAP12 form distinct, but functionally cooperative, receptor complexes in natural killer cells. J Exp Med 2000;192:1059-68.
134. Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL, Phillips JH.. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999;285:730-32
135. Yao L, Sgadari C, Furuke K, Bloom ET, Teruya-Feldstein J, Tosato G. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 1999;93:1612-21.
136. Young HA, Ortaldo JR, Herberman RB, Reynolds CW. Analysis of T cell receptors in highly purified rat and human large granular lymphocytes (LGL): lack of functional 1.3 kD beta-chain mRNA. J Immunol 1986;136:2701-4.
137. Young WW Jr, Hakomori SI, Durdik JM, Henney CS. Identification of ganglio-N-tetraosylceramide as a new cell surface marker for murine natural killer (NK) cells. J Immunol 1980;124:199-201.
138. Zeidler R, Eissner G, Meissner P, Uebel S, Tampe R, Lazis S, Hammerschmidt W. Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10. Blood 1997;90:2390-7.
139. Zhang D, Beresford PJ, Greenberg AH, Lieberman J Granzymes A and B directly cleave laminins and disrupt the nuclear lamina during granule-mediated cytolysis. Proc Natl Acad Sci USA 2001;98:5746-51.